Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 18, 2016

View Archived Issues

Viiv Healthcare starts phase III trial for two-drug regimen of dolutegravir/lamivudine

BioNano Genomics and Berry Genomics to codevelop next-generation mapping system

Studies in vivo show serine 421 to be a therapeutic target in Huntington's disease

Hutchison MediPharma patents PI3K inhibitors

Karos reports phase I outcomes for KAR-5585

Vanderbilt University describes mgluR4 positive allosteric modulators

FDA clears Trillium Therapeutics to start phase I trial of TTI-621

CRLX-101 plus bevacizumab does not show improvement compared to SoC in relapsed RCC

Cancer Genetics receives New York State approval for Focus::Myeloid

Children's Hospital Los Angeles initiates phase I trial of durvalumab in pediatric cancer patients

FDA issues complete response letter for AndexXa BLA

European Commission approves Cinqaero for severe eosinophilic asthma

Symbiomix Therapeutics accelerates commercial launch for Solosec

FDA grants orphan drug designation to Pulmatrix's PUR-1900

SMAD7 gene therapy may ameliorate cancer cachexia

Targeting MondoA-directed pathway for the treatment of insulin resistance and lipotoxicity

Janssen submits sBLA to FDA for Darzalex in relapsed multiple myeloma

Avexis reports data from ongoing phase I trial of AVXS-101 for type 1 SMA

NIH grant supports phase II trial of IMM-124-E in pediatric NASH

Quidel obtains FDA clearance to market Solana Trichomonas assay

Data from phase I studies reported for diabetes candidate LGD-6972

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...